Related Experiment Video

Updated: Oct 11, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K

Receptor Interacting Protein Kinases 1/3: The Potential Therapeutic Target for Cardiovascular Inflammatory Diseases

Yiming Leng1, Ying Zhang2, Xinyu Li3

  • 1Clinical Research Center of the 3rd Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Pharmacology
|December 6, 2021
PubMed

Insights

Receptor interacting protein kinases 1/3 (RIPK1/3) are key in cell death and inflammation. This review details RIPK1/3 roles in cardiovascular diseases, focusing on necroptosis and therapeutic targets.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Biology
  • Cellular Biology

Background:

  • Receptor interacting protein kinases 1 and 3 (RIPK1/3) are crucial mediators of cell death pathways and inflammatory signaling.
  • Dysregulation of RIPK1/3 activity, through ubiquitination, phosphorylation, or inhibition, significantly impacts necroptosis and apoptosis.
  • Growing research highlights the involvement of RIPK1/3 in cardiovascular disease pathogenesis and inflammatory responses.

Purpose of the Study:

  • To elaborate on the mechanisms of RIPK1/3-mediated necroptosis.
  • To review the latest regulatory molecules and therapeutic targets associated with RIPK1/3 in cardiovascular diseases.
  • To explore the interplay between autophagy and necroptosis in cardiomyocyte death.

Main Methods:

  • Literature review and synthesis of existing research on RIPK1/3.
  • Analysis of RIPK1/3 involvement in various cardiovascular conditions.
  • Identification of regulatory pathways and potential therapeutic strategies.

Main Results:

  • RIPK1/3 play a central role in regulating programmed cell death, including necroptosis and apoptosis.
  • The crosstalk between autophagy and necroptosis is a significant factor in cardiomyocyte death.
  • RIPK1/3 are implicated in diverse cardiovascular pathologies such as ischemia-reperfusion injury, atherosclerosis, and myocarditis.

Conclusions:

  • RIPK1/3 are critical regulators of cell death and inflammation in cardiovascular diseases.
  • Understanding RIPK1/3-mediated pathways offers potential for novel therapeutic interventions.
  • Targeting RIPK1/3 and related molecules presents a promising avenue for treating cardiovascular conditions.
Keywords:
RIPK1RIPK3cardiovascular diseasesnecroptosistherapeutic

More Related Videos

A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation12:55

A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation

Published on: December 9, 2021

3.4K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

649

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
281
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
274
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
561
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
258